Treatment: Cancidas is indicated for empirical therapy for presumed fungal infections in febrile, neutropenic patients.
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5514650 | MERCK | Aza cyclohexapeptide compounds |
Jan, 2015
(10 years ago) | |
| US5792746 | MERCK | Aza cyclohexapeptide compounds |
Mar, 2013
(12 years ago) | |
| US6136783 | MERCK | Antifungal compositions |
Mar, 2017
(8 years ago) | |
|
US5792746 (Pediatric) | MERCK | Aza cyclohexapeptide compounds |
Sep, 2013
(12 years ago) | |
|
US5378804 (Pediatric) | MERCK | Aza cyclohexapeptide compounds |
Sep, 2013
(12 years ago) | |
| US5378804 | MERCK | Aza cyclohexapeptide compounds |
Mar, 2013
(12 years ago) | |
| US5952300 | MERCK | Antifungal compositions |
Mar, 2017
(8 years ago) | |
|
US5514650 (Pediatric) | MERCK | Aza cyclohexapeptide compounds |
Jul, 2015
(10 years ago) | |
|
US5952300 (Pediatric) | MERCK | Antifungal compositions |
Sep, 2017
(8 years ago) | |
|
US6136783 (Pediatric) | MERCK | Antifungal compositions |
Sep, 2017
(8 years ago) | |
Drugs and Companies using CASPOFUNGIN ACETATE ingredient
Market Authorisation Date: 26 January, 2001
Dosage: POWDER